Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Special Report by Heritage Foundation: A Statistical Analysis of COVID-19 and Government Protection Measures in the U.S.

The Heritage Foundation released a Special Report that conducts a statistical analysis of COVID-19 data. The report begins by examining Centers for Disease Control and Prevention data and analyzing the spread and mortality of COVID-19 throughout 2020, identifying specific facets of the population at most risk. The authors then conduct an analysis of the geographic spread of COVID-19, finding that the disease has largely been concentrated in varying hotspots throughout the course of the year. Subsequently, the authors conduct an analysis of Google mobility data to understand the public’s response to COVID-19 before and after the virus had been declared a pandemic. Lastly, the authors conduct a survival analysis examining the effect of behavioral responses to COVID-19 alongside government policies. The authors’ work provides insights to policymakers to continue to combat COVID-19 as well as to prepare for future potential public health crises.

Source: Heritage Foundation

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!